SIENA, Italy, Oct. 8, 2020 /PRNewswire/ — Philogen S.p.A., a clinical-stage biotechnology firm centered on antibody-based therapeutics, is happy to announce the publication of a peer-reviewed scientific article in Science Translational Drugs. The article is entitled: “Immunocytokines are a promising immunotherapeutic method in opposition to glioblastoma” (T. Weiss, E. Puca, M. Silginer, T. Hemmerle, S. Pazahr, A. Bink, M. Weller, D. Neri, P. Roth, Immunocytokines are a promising immunotherapeutic method in opposition to glioblastoma. Sci. Transl. Med. 12, eabb2311 (2020)) and will be accessed here.
The findings of the research present how Philogen’s proprietary antibody-cytokine fusions, referred to as immunocytokines, demonstrated hanging single-agent anti-cancer exercise in immunocompetent preclinical fashions bearing orthotopic glioblastoma. Furthermore, the therapy induced long-term tumor eradications in a proportion of the handled animals. These findings had been of specific relevance as preclinical fashions with glioblastoma can’t be cured by any present normal of care.
The article additionally discusses preliminary medical outcomes of the primary sufferers recruited within the PH-L19TNFGLIO-02/18 Part I/II trial. Early findings confirmed that Philogen’s proprietary therapy, onkekafusp alpha (L19TNF), when used as a monotherapy induced not solely a selective tumor necrosis in all sufferers (evidenced by contrast-enhanced and perfusion Magnetic Resonance Imaging), but in addition supplied circumstances of extended illness stabilization. Throughout the research, the therapy was proven to be protected and properly tolerated.
The continuing Part I/II medical research (PH-L19TNFGLIO-02/18, https://clinicaltrials.gov/ct2/show/NCT03779230) is investigating the usage of L19TNF as a single-agent for the therapy of high-grade glioma at first recurrence/relapse, a affected person inhabitants with an in any other case very poor prognosis. TNF is delivered to most cancers lesions by the L19 antibody particular to the EDB area of Fibronectin, a marker for angiogenesis that’s expressed in just about all sufferers with malignant glioma. The Firm has beforehand demonstrated by nuclear drugs procedures in additional than 50 sufferers, that the L19 antibody may effectively localize in major and secondary mind tumors.
The part I/II research is open label, in topics with glioblastoma at first recurrence/relapse and shall be carried out in two elements: (i) a dose discovering half to find out the beneficial dose of L19TNF (the info of this a part of the research are revealed within the paper), (ii) adopted by a sign looking for half that investigates first indicators of exercise.
“We’re very excited in regards to the glorious preclinical outcomes obtained in collaboration with Philogen, which is a frontrunner within the discipline of focused supply of cytokine therapeutics. The rising medical outcomes of the continuing research with L19TNF in glioblastoma – essentially the most malignant mind tumor – gives hope for another therapeutic alternative for sufferers affected by this horrible illness. In a subsequent step, we intention at understanding the potential of L19TNF by investigating the product in bigger randomised trials.” commented Prof. Michael Weller, Chairman of the Division of Neurology on the College Hospital in Zurich.
Prof. Dario Neri, Co-Chief Govt Officer of Philogen, added: “Our therapy is demonstrating effectiveness at switching the immunologically chilly glioma microenvironment right into a scorching one, enabling efficient antitumor immunity. We’re delighted with the progress being made with our immunocytokine and are happy with the good promise this might deliver to sufferers with malignant mind tumors.”
The medical research is led by Prof. Michael Weller, Dr. Patrick Roth and Dr. Tobias Weiss on the Division of Neurology of the College of Zurich. Philogen acts because the sponsor of the trial.
Philogen is a Swiss-Italian clinical-stage firm engaged within the discovery and growth of novel pharmaceutical and biopharmaceutical merchandise. Philogen’s technique is to ship bioactive brokers, for instance cytokines or medication, to the location of illness utilizing antibodies and different ligands that particularly and effectively goal stromal antigens. This expertise has generated a robust proprietary pipeline of clinical-stage merchandise and preclinical compounds in an array of illness indications. Philogen is headquartered in Siena, Italy, and has analysis actions at its subsidiary firm Philochem in Zürich, Switzerland. Philogen is independently owned, and has signed agreements with a number of main pharmaceutical corporations. For extra info please go to www.philogen.com and www.philochem.com.
For extra info please contact:
Dr. Christian Lizak
+41 (0) 43 544 88 00
Consilium Strategic Communications
Mary-Jane Elliott, Melissa Gardiner
SOURCE Philogen S.p.A.